Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial

(2013) Juan C. Arjona Ferreira et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

(2013) Samuel S Engel et al.   Cardiovascular Diabetology

Incretin Therapy and Islet Pathology: A Time for Caution

(2013) S. E. Kahn   DIABETES

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

(2013) M. A. Nauck   DIABETES CARE

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

(2013) P. C. Butler et al.   DIABETES CARE

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

(2013) W. B. White et al.   DIABETES OBESITY & METABOLISM

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

(2013) Y. G. Kim et al.   DIABETOLOGIA

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

(2013) Andre Scheen   Expert Opinion On Drug Safety

Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation

(2013) Johannes Werzowa et al.   TRANSPLANTATION

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

(2013) D. Cohen   BMJ-British Medical Journal

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

(2013) Samuel S. Engel et al.   Diabetes Therapy

Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus

(2012) Harshal R. Patil et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

(2012) Haesuk Park et al.   ANNALS OF PHARMACOTHERAPY

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

(2012) Vanita R. Aroda et al.   CLINICAL THERAPEUTICS

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

The Human GLP-1 Analog Liraglutide and the Pancreas

(2012) Niels C.B. Nyborg et al.   DIABETES

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study

(2012) B. Guerci et al.   DIABETES & METABOLISM

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

(2012) M. R. Rizzo et al.   DIABETES CARE

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

(2012) J. C. Arjona Ferreira et al.   DIABETES CARE

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

(2012) C. F. Deacon et al.   DIABETES OBESITY & METABOLISM

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

(2012) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk

(2012) K. G. Brodovicz et al.   DIABETES OBESITY & METABOLISM

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man

(2012) S. J. Busch et al.   DIABETES OBESITY & METABOLISM

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

(2012) K. Gooßen et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: A case report and a review of the literature

(2012) Shinya Furukawa et al.   ENDOCRINE JOURNAL

Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting

(2012) Howard Lando et al.   Endocrine Practice

Type 2 diabetes mellitus and the risk of acute pancreatitis

(2012) Lin Yang et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study

(2012) Scott R. Goodwin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research

(2012) Berthold Hocher et al.   KIDNEY & BLOOD PRESSURE RESEARCH

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

(2011) Kathleen R. Richard et al.   CLINICAL THERAPEUTICS

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

(2011) Nir Barzilai et al.   CURRENT MEDICAL RESEARCH AND OPINION

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

(2011) Matteo Monami et al.   CURRENT MEDICAL RESEARCH AND OPINION

A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction: A reanalysis of the HEART2D study

(2011) S. E. Siegelaar et al.   DIABETES CARE

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

(2011) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

(2011) Midori Ito et al.   ENDOCRINE JOURNAL

Vildagliptin-Induced Acute Pancreatitis

(2011) Christian Girgis et al.   Endocrine Practice

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

(2011) Cristina Mega et al.   Experimental Diabetes Research

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

(2011) L. Cai et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Comments on the article “Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations” by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79–83)

(2011) Angelo Avogaro   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Reply to the “Comments on the article ‘Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations’”, by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352–353)

(2011) Raffaele Marfella et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation

(2011) James T. Lane et al.   TRANSPLANTATION

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

(2010) Krystyna Tatarkiewicz et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1 

(2010) G. P. Fadini et al.   DIABETES CARE

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

(2010) C. J. Girman et al.   DIABETES OBESITY & METABOLISM

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

(2010) M. Ligueros-Saylan et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

(2010) C. F. Deacon   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

(2010) André J. Scheen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

(2010) R. Garg et al.   DIABETIC MEDICINE

Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]

(2010) Sachiko Hattori   ENDOCRINE JOURNAL

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis

(2010) Hans D. Theiss et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

(2010) T. Seck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

(2010) S. S. Engel et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database

(2010) B. Cai et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction

(2009) Marc-Michael Zaruba et al.   Cell Stem Cell

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice

(2009) J. A. Koehler et al.   DIABETES

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes

(2009) E. S. Kilpatrick et al.   DIABETES CARE

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

(2009) J. S. Nachnani et al.   DIABETOLOGIA

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

(2009) Raffaele Marfella et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

(2009) Richard E. Pratley et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Glucagon-like peptide-1, glucose homeostasis and diabetes

(2008) Jens J. Holst et al.   TRENDS IN MOLECULAR MEDICINE